Cycle Pharmaceuticals and Catalent partner to develop treatments for rare diseases using Zydis ODT technology

This article was originally published here

This agreement covers four products in rare metabolic and neurological disorders and each product will utilise Catalent’s Zydis® oral disintegrating tablet (ODT) and Zydis Ultra® technologies. Zydis technology

The post Cycle Pharmaceuticals and Catalent partner to develop treatments for rare diseases using Zydis ODT technology appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply